Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 170

1.

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.

de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TC, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IE, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL.

Arthritis Res Ther. 2016 Feb 17;18:49. doi: 10.1186/s13075-016-0946-9.

2.

B cell signature contributes to the prediction of RA development in patients with arthralgia.

Lübbers J, Vosslamber S, van de Stadt LA, van Beers-Tas M, Wesseling JG, von Blomberg BM, Witte BI, Bontkes HJ, van Schaardenburg D, Verweij CL.

Ann Rheum Dis. 2015 Sep;74(9):1786-8. doi: 10.1136/annrheumdis-2015-207324. Epub 2015 May 27. No abstract available.

PMID:
26019192
3.

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.

de Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ, Jansen G, Voskuyl AE, Verweij CL.

Arthritis Res Ther. 2015 Mar 23;17:78. doi: 10.1186/s13075-015-0564-y.

4.

Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.

Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29.

5.

Moving towards personalized medicine in rheumatoid arthritis.

de Jong TD, Vosslamber S, Verweij CL.

Arthritis Res Ther. 2014;16(3):110.

6.

Gene expression analysis in RA: towards personalized medicine.

Burska AN, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, Verweij CL, Rowe A, Goulielmos GN, van Baarsen LG, Ponchel F.

Pharmacogenomics J. 2014 Apr;14(2):93-106. doi: 10.1038/tpj.2013.48. Epub 2014 Mar 4. Review.

7.

Sex differences in the human peripheral blood transcriptome.

Jansen R, Batista S, Brooks AI, Tischfield JA, Willemsen G, van Grootheest G, Hottenga JJ, Milaneschi Y, Mbarek H, Madar V, Peyrot W, Vink JM, Verweij CL, de Geus EJ, Smit JH, Wright FA, Sullivan PF, Boomsma DI, Penninx BW.

BMC Genomics. 2014 Jan 17;15:33. doi: 10.1186/1471-2164-15-33.

8.

Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis.

Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Vosslamber S, Verweij CL, Olsen NJ, Aune TM.

J Clin Bioinforma. 2013 Oct 3;3(1):18. doi: 10.1186/2043-9113-3-18.

9.

Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis.

Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Wolbink GJ, Vosslamber S, Verweij CL.

Arthritis Rheum. 2013 Nov;65(11):2791-802. doi: 10.1002/art.38094.

10.

The type I IFN signature as a biomarker of preclinical rheumatoid arthritis.

Lübbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, Rantapää-Dahlqvist S, Verweij CL.

Ann Rheum Dis. 2013 May;72(5):776-80. doi: 10.1136/annrheumdis-2012-202753. Epub 2013 Feb 23.

PMID:
23434571
12.

Research highlights: Clinical relevance of the type I interferon signature in multiple sclerosis.

Verweij CL.

Pharmacogenomics. 2012 Dec;13(16):1883-5. doi: 10.2217/pgs.12.166. No abstract available.

PMID:
23215880
13.

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE.

Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819.

14.
15.

Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.

Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ, Aune TM.

Genes Immun. 2012 Feb;13(2):146-54. doi: 10.1038/gene.2011.66. Epub 2011 Sep 22.

16.

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.

Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdóttir S, Rao R, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES).

Ann Rheum Dis. 2011 Oct;70(10):1713-8. doi: 10.1136/ard.2011.154252. Epub 2011 Jul 22. Review.

PMID:
21784723
17.

Combining DNA-microarray data in systemic lupus erythematosus.

Verweij CL, Vosslamber S.

Genome Med. 2011 May 31;3(5):30. doi: 10.1186/gm246.

18.

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.

Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der Pouw Kraan TC, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL.

Genes Immun. 2011 Sep;12(6):466-72. doi: 10.1038/gene.2011.18. Epub 2011 Apr 7. Erratum in: Genes Immun. 2012 Jul, 13(5):443. van der PouwKraan, T C T M [corrected to van der Pouw Kraan, TCTM].

PMID:
21471993
19.

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.

Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl AE, Verweij CL.

Ann Rheum Dis. 2011 Jun;70(6):1153-9. doi: 10.1136/ard.2010.147199. Epub 2011 Mar 27.

PMID:
21444302
20.

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?

Verweij CL.

Nat Rev Rheumatol. 2011 Mar;7(3):136-8. doi: 10.1038/nrrheum.2011.13. Epub 2011 Feb 8.

PMID:
21304506
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk